NEWBRY — Newbury Pharmaceuticals AB Share News
0.000.00%
Last trade - 00:00- SEK63.23m
- SEK48.55m
- SEK31.57m
Brief: Newbury Signs Licence And Supply Deal For Guanfacine
Brief: Newbury Pharmaceuticals Gets Approval for Tofacitinib Newbury
Brief: Newbury Pharmaceuticals Secures Generic Approval For Dalbavancin Newbury
Brief: Newbury Pharmaceuticals Reports Q3 EBITDA Of SEK -4 Mln
Sweden's Newbury Pharmaceuticals Q3 revenue rises on portfolio expansion
Brief: Newbury Pharmaceuticals Q2 EBITDA Loss Deepens To SEK 4.1 Million
Brief: Newbury Pharmaceuticals Enters Into New Partnership
Brief: Newbury Pharmaceuticals Says Projected Nordic Q1 Turnover Within Reach
Brief: Newbury Pharmaceuticals Appoints Karl Karlsson As CEO
Brief: Newbury Pharmaceuticals Secures Generic Approval For Mirtazapin Newbury
Brief: Newbury Pharmaceuticals Gets Generic Approval For Ivermectin Newbury
Brief: Newbury Secures Generic Approval For Melatonin Newbury
Brief: Newbury EBITDA Loss For Q3 Narrows To SEK 5.7 Mln
Brief: Newbury Pharmaceuticals Q2 EBITDA Loss SEK 1 Mln
Brief: Newbury Pharmaceuticals Secures Approval For Macitentan Film-Coated Tablets In Denmark
Brief: Newbury Pharmaceuticals Secures Generic Approval For Pomalidomide Capsules
Brief: Newbury Pharmaceuticals Q1 EBITDA Loss Widens To SEK 3.76 Mln
Brief: Newbury Pharmaceuticals Secures Generic Approval For Buspiron
Brief: Newbury Pharmaceuticals Q4 EBITDA Turns To Profit Of SEK 2.4 Mln